ONCOZENGE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.895 SEK | +0.13% |
|
-5.23% | +26.05% |
| 04-08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
| 04-04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 45.62M 499M 3.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -87.52M -640M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | 3M 32.82M 240M | Net cash position 2025 * | 3M 32.82M 240M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.73
x | P/E ratio 2025 * |
-
| Employees | 2 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.35% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.13% | ||
| 1 week | -5.23% | ||
| Current month | +14.56% | ||
| 1 month | +11.29% | ||
| 3 months | -48.61% | ||
| 6 months | +31.81% | ||
| Current year | +26.05% |
1 week
3.72
4.39
1 month
3.204.50
Current year
2.807.96
1 year
1.6010.56
3 years
1.6015.00
5 years
1.6017.60
10 years
1.6017.60
| Managers | Title | Age | Since |
|---|---|---|---|
Stian Kildal
CEO | Chief Executive Officer | - | 12/09/23 |
Michael Owens
DFI | Director of Finance/CFO | 68 | 11/10/23 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 30/04/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christoph Nowak
BRD | Director/Board Member | 38 | 08/09/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.895 | +0.13% | 32,174 |
| 25/04/24 | 3.89 | -9.43% | 75,144 |
| 24/04/24 | 4.295 | +6.18% | 18,193 |
| 23/04/24 | 4.045 | -3.80% | 13,212 |
| 22/04/24 | 4.205 | +2.31% | 25,812 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotes
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.
Sector
Pharmaceuticals
Calendar
20/05/2024
- Q1 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.05% | 4.16M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ONCOZ Stock
